Recent Posts

Europe’s soft response to terror isn’t weak

  A top Bavarian domestic intelligence official has made tabloid headlines by saying there are “hit squads” and “sleeper cells” among the refugees who have recently arrived in Germany — something right-wing populists have been maintaining all along. Yet the true “sleeper cells” have been here for decades, and that explains why, as Germany and other European countries step up ...

Read More »

Don’t be afraid of the eerie calm in US stocks

  Nir Kaissar There’s a strange disconnect today between some investors’ trepidation about US stocks and the soothing signals coming from the equity market. As my Bloomberg colleague Barry Ritholtz recently noted, a whole bunch of high-profile money mavens — Stan Druckenmiller, George Soros and Bill Gross included — are kvetching about the dangers lurking in U.S. shares (among other ...

Read More »

Concordia on the wrong side of pharma history

  Max Nisen Disappointing earnings. Substantially lower guidance for 2016. A CFO departure. A suspended dividend. A drug-pricing controversy. Oh, and a libel suit against a chicken farmer. All were features of Concordia International’s unusually calamitous earnings report on Friday. For a day, at least, the Ontario-based specialty pharma firm one-upped its better-known progenitor Valeant, which has had a mixed ...

Read More »
Send this to a friend